Core Viewpoint - Next week, a total of 38 stocks will be unlocked, with a combined market value of 39.63 billion yuan based on the latest closing prices [2]. Group 1: Stock Unlocking Details - Ningbo Yiyang will have 1.06 billion shares listed for circulation, primarily from the original shareholders' restricted shares, with an unlocking market value of 9.71 billion yuan [3]. - EVE Energy ranks second in unlocking market value, with 125 million shares to be unlocked, mainly from the placement of shares to targeted investors, totaling 8.62 billion yuan [3]. - In contrast, Longxun Co., Xinghao Pharmaceutical, and Yinlong Co. have relatively low unlocking pressure, with unlocking market values of less than 10 million yuan each [4]. Group 2: Unlocking Proportions - The stocks with the highest unlocking ratios include Ningbo Yiyang, Oke Technology, and Jingpin Special Equipment, all exceeding 50% [5]. Group 3: Institutional Attention - Eight stocks facing unlocking have garnered significant institutional attention, with over 30 institutions conducting research since the fourth quarter [7]. - Among these, Juhe Materials has a market value of 1.056 billion yuan facing unlocking, and has received research from 161 institutions. The company specializes in the research, production, and sales of fluorochemical products [8]. - Huadong Medicine has received research from 132 institutions and has begun exporting some of its pharmaceutical products internationally, while also expanding its medical aesthetics business globally [9]. Group 4: Stock Performance - Among the 38 stocks facing unlocking, the average stock price has decreased by 0.14% since December [8]. - Changying Tong has the highest price increase, with a cumulative rise of 9.94% in December, while Sanfu Xinke has the largest decline, with a cumulative drop of 12.37% [8].

（文章来源：证券日报） 证券日报网讯 12月5日晚间，华东医药发布公告称，公司2022年限制性股票激励计划首次授予限制性股 票第三个解除限售条件成就，本次符合解除限售条件的激励对象共计77人，可解除限售的限制性股票数 量为127.512万股，占目前公司总股本的0.07%，上市流通日为2025年12月10日。 ...

（编辑 楚丽君） 证券日报网讯 12月5日，华东医药在互动平台回答投资者提问时表示，公司高度重视国际化战略，公司 医药工业板块目前已有部分制剂产品出口国际市场，创新药业务在强化自主研发的同时，也将积极与全 球同行一起探索创新药管线的BD机会。 ...

证券代码：000963 证券简称：华东医药 公告编号：2025-109 华东医药股份有限公司 关于2022年限制性股票激励计划首次授予限制性股票第三 个解除限售期解除限售股份上市流通的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、公司 2022 年限制性股票激励计划首次授予限制性股票第三个 解除限售条件成就，本次符合解除限售条件的激励对象共计 77 人， 可解除限售的限制性股票数量为 127.512 万股，占目前公司总股本的 0.07%。 2、本次解除限售的限制性股票上市流通日为 2025 年 12 月 10 日。 华东医药股份有限公司（以下简称"华东医药"、"公司"）于 2025 年 11 月 20 日召开第十一届董事会第五次会议，审议通过了《关于 2022 年限制性股票激励计划首次授予限制性股票第三个解除限售期 解除限售条件成就的议案》。根据《上市公司股权激励管理办法》公 司《2022 年限制性股票激励计划》（以下简称"《激励计划》"）的相 关规定及公司 2022 年第一次临时股东大会的授权，公司为符合条件 的激励对象办理了解 ...

（记者 王晓波） 每经AI快讯，华东医药（000963.SZ）12月5日在投资者互动平台表示，公司高度重视国际化战略，公司 医药工业板块目前已有部分制剂产品出口国际市场，创新药业务在强化自主研发的同时，也将积极与全 球同行一起探索创新药管线的BD机会；医美板块实行全球化运营，医美营销网络已覆盖全球80多个国 家和地区，拥有海内外已上市产品二十余款，在研全球创新产品十余款，致力于成为全球领先的医美综 合解决方案提供商；工业微生物板块持续拓展海外市场，特色原料药&中间体、xRNA业务已与多家海 外药企建立合作关系，销售规模稳定增长，客户数量稳步增加。具体进展和计划详见公司以往及后续发 布的相关公告及定期报告。 ...

看得远的人才能走得远。这话对企业发展来说同样适用。发言中，尽管不少企业提及今年还不错的成绩 单，但是对未来，依然保持谨慎。 拿新能源汽车来说，今年浙产新能源汽车一路高歌猛进。上半年，浙江新能源汽车产量达到50.98万 辆，位居全国第四。 12月4日，浙江省委书记王浩在杭州主持召开企业家和专家学者座谈会，听取对明年经济形势和经济工 作的意见建议。 面对战略机遇和风险挑战并存的发展环境，明年经济走向如何，行业发展透出什么新机，哪些难点亟待 解决……这些问题，都让这场座谈会备受关注。 参加座谈会的，是各行各业的大咖。 企业家分别是浙江吉利控股集团董事长李书福、网易集团副总裁刘杰、阿里巴巴集团天猫总裁刘博、舜 宇光学科技（集团）有限公司总裁王文杰、华东医药股份有限公司董事长吕梁、思看科技（杭州）股份 有限公司董事长兼总经理王江峰、浙江中国小商品城集团股份有限公司董事长陈德占等。 专家则有浙江大学文科资深教授史晋川，省咨询委副主任、秘书长孟刚，省发展规划研究院院长李军 等。 与会企业是浙江优势产业的代表，他们率先遇到的"成长烦恼"和发展机遇，虽是个例，却也极具行业代 表性。置身其中，听他们谈信心、讲问题，记者捕捉到了这 ...

Investment Rating - The investment rating for the industry is "Positive" and the rating has been maintained [2] Core Views - The pharmaceutical and biotechnology industry index experienced a decline of 4.40%, ranking 23rd among 31 primary industries, underperforming the CSI 300 index which fell by 2.19% [6][18] - The valuation of the pharmaceutical and biotechnology industry as of November 28, 2025, is a PE (TTM overall method, excluding negative values) of 29.46x, down from 30.89x in the previous period, indicating a downward trend and below the average [22] - The report highlights potential beneficiaries from the upcoming ASH data, particularly in blood diseases and companies with solid grassroots channels, as well as those with differentiated advantages in oncology, autoimmune, and rare disease products [10] Summary by Sections Industry Review - The pharmaceutical and biotechnology industry index fell by 4.40%, with chemical preparations and medical devices showing declines of 2.86% and 2.95% respectively, while offline pharmacies and vaccines saw larger declines of 8.22% and 6.42% [6][18] - The PE ratio for the pharmaceutical and biotechnology industry is 29.46x, with the highest valuations in the vaccine (47.56x), hospital (41.17x), and medical device (36.77x) sectors, while pharmaceutical circulation has the lowest at 14.58x [22] Important Industry News - The National Administration of Traditional Chinese Medicine and the National Healthcare Security Administration released a directory for traditional Chinese medicine diseases suitable for disease-based payment [26][27] - AstraZeneca's drug "Durvalumab" received FDA approval for a new indication in perioperative treatment of gastric cancer [32] - Otsuka Pharmaceutical's new drug for IgA nephropathy, "Sibeprenlimab," has been approved by the FDA [38] - Bayer's first-in-class lung cancer drug "Sevabertinib" has been approved by the FDA for specific patient populations [40] Investment Recommendations - Focus on innovative pharmaceutical companies that may benefit from the medical insurance or commercial insurance directories, blood cancer targets with imminent ASH data releases, and biotech and CXO leaders with solid technology platforms and international collaboration expectations [10]

Investment Rating - The report maintains an "Outperform" rating for A-Shares including Jiangsu Heng Rui Medicine, Sichuan Kelun Pharmaceutical, Huadong Medicine, Jiangsu Nhwa Pharmaceutical, Xiamen Amoytop Biotech, Zhejiang Jingxin Pharmaceutical, Innovent Biologics, WuXi AppTec, Hangzhou Tigermed Consulting, Lepu Medical, and APT Medical [2][4][29] - The report also maintains an "Outperform" rating for H-Shares including Hansoh Pharmaceutical Group, 3SBio, PATEO, Akeso, and related targets such as Innovent Biologics and WuXi AppTec (H-Shares) [2][7][29] Core Insights - The report continues to recommend the innovative drug and device industry chain [1][2] - In November 2025, the pharmaceutical sector underperformed the broader market, with the SW Pharma Bio index falling by 3.6% compared to a 1.7% drop in the SHCOMP [2][10] - The premium of the pharmaceutical sector to all A-Shares is currently at a normal level of 72.6% as of the end of November 2025 [17][22] Summary by Sections A-Shares Performance - The report highlights the A-Shares that are recommended for investment, maintaining an "Outperform" rating for several companies, including Jiangsu Heng Rui Medicine and Sichuan Kelun Pharmaceutical, among others [4][5] - The report notes that the pharmaceutical sector's performance was ranked 23rd among Shenwan's first-level industries in November 2025 [10][12] H-Shares Performance - The report indicates that the H-Shares pharmaceutical sector performed in line with the market, with the Hang Seng Healthcare index down by 0.1% and the biotech sector up by 0.4% in November 2025 [2][23] - Top gainers in the H-Shares market included Laekna, Inc. (+40%) and Clover Biopharmaceuticals, Ltd. (+22%) [23] U.S. Market Performance - The U.S. pharmaceutical sector outperformed the broader market in November 2025, with the S&P Healthcare Select Sector rising by 9.1% compared to a 0.1% increase in the S&P 500 [23]

Core Viewpoint - The report highlights the trends and statistics in the Chinese chemical pharmaceutical industry, indicating a slight decline in production while maintaining overall growth in the first nine months of 2025 [1]. Industry Summary - In September 2025, the production of chemical pharmaceutical raw materials in China was 295,000 tons, representing a year-on-year decrease of 3.6% [1]. - Cumulatively, from January to September 2025, the total production of chemical pharmaceutical raw materials reached 2.721 million tons, showing a cumulative growth of 1.2% [1]. - The report is based on data from the National Bureau of Statistics and is compiled by Zhiyan Consulting, a leading industry consulting firm in China [1]. Company Summary - Listed companies in the chemical pharmaceutical sector include Heng Rui Medicine (600276), East China Pharmaceutical (000963), Lizhu Group (000513), Baiyunshan (600332), North China Pharmaceutical (600812), Haizheng Pharmaceutical (600267), Fosun Pharmaceutical (600196), Kelun Pharmaceutical (002422), Enhua Pharmaceutical (002262), and Xianju Pharmaceutical (002332) [1].

Investment Rating - The report maintains a positive outlook on the innovative drug sector, indicating a rebound and potential for further growth in the upcoming months [3][6]. Core Insights - The innovative drug sector is expected to see a rebound after previous adjustments, with significant catalysts anticipated in December and January. The results of the national medical insurance negotiations will be released in early December, which may impact the inclusion of domestic innovative drugs in the insurance catalog [3][14]. - The upcoming American Society of Hematology (ASH) conference from December 6-9 is highlighted as a key event, with multiple differentiated hematology products expected to present new data [3][4][42]. - The CXO sector shows a continuous upward trend, supported by the rapid growth of new orders and backlog, ensuring performance release in the next 1-2 years [4][53]. Summary by Sections Innovative Drugs - The report emphasizes the importance of focusing on dual/multi-target drugs for various cancers and chronic diseases, as well as opportunities in ADCs and small nucleic acid therapies [6][15]. - The report notes that the innovative drug financing data is showing marginal improvement, indicating a potential recovery in the sector [6][15]. Biologics - The report mentions positive preliminary results from the Phase II clinical trial of amycretin for Type 2 diabetes, suggesting continued monitoring of its clinical progress [4][46]. Medical Devices - The report highlights the emergence of innovative domestic medical devices, with expectations for profit margins to stabilize and improve as new products are approved [5]. Traditional Chinese Medicine & Pharmacies - The report suggests monitoring companies with strong brand power and good inventory management, such as China Resources Sanjiu and Jichuan Pharmaceutical, due to rising flu incidence [5]. Medical Services and Consumer Healthcare - The report discusses a collaboration between a traditional Chinese medicine group and a local health bureau to enhance the capabilities of grassroots medical services through technology [5]. Key Investment Targets - The report identifies key companies to watch, including Innovent Biologics, Kintor Pharmaceutical, and others in the innovative drug and medical device sectors [7].